慢性乙型肝炎抗病毒治疗中无创纤维化标志物应答可预测肝细胞癌
多中心研究纳入5,147例接受恩替卡韦/替诺福韦治疗超过12个月的慢性乙型肝炎患者,评估治疗中基于4因子的纤维化指数和AST/血小板比值指数的变化与肝细胞癌发生的关系。研究发现12个月内无创纤维化标志物显著下降与肝细胞癌风险显著降低相关,并据此建立FSAC评分,其10年预测C-index高于PAGE-B等现有模型。
要点
- 治疗中无创纤维化标志物应答是肝细胞癌的独立预测因素。
- FSAC评分整合纤维化标志物应答、性别、年龄和肝硬化,预测性能优于PAGE-B等模型。
- 12个月内无创纤维化标志物显著下降者肝细胞癌风险明显降低。
核心结论
- 治疗中无创纤维化标志物的变化是肝细胞癌风险的独立指标。
- 包含无创纤维化标志物应答的FSAC评分是可靠的肝细胞癌风险预测工具,性能优于其他模型。
研究设计与样本
- 多中心研究纳入5,147例慢性乙型肝炎患者,其中推导队列4,028例,验证队列1,119例。
- 患者于2007至2018年间接受恩替卡韦/替诺福韦治疗超过12个月。
- 基于多变量Cox模型建立肝细胞癌风险预测模型,并采用bootstrapping进行验证。
主要发现
- 推导队列和验证队列的10年累积肝细胞癌发生率分别为12.6%和13.7%。
- 12个月内无创纤维化标志物显著下降的患者肝细胞癌风险明显降低(P < 0.001)。
- 无创纤维化标志物应答、性别、年龄和肝硬化是肝细胞癌的独立预测因素。
- FSAC对10年肝细胞癌预测的C-index高于PAGE-B、改良PAGE-B、CU-HCC和REACH-B(分别为0.84 vs 0.77、0.80、0.77和0.67;所有P < 0.005)。
- 验证队列中FSAC的C-index仍高于其他模型(所有P < 0.050)。
关键数值与推荐
- FSAC评分基于纤维化标志物应答、性别、年龄和肝硬化各变量的回归系数构建。
- FSAC对10年肝细胞癌预测的C-index为0.84,高于PAGE-B的0.77、改良PAGE-B的0.80、CU-HCC的0.77和REACH-B的0.67(所有P < 0.005)。
临床怎么用
- 对接受恩替卡韦/替诺福韦治疗的慢性乙型肝炎患者,可动态评估无创纤维化标志物应答以辅助肝细胞癌风险分层。
- FSAC评分可用于10年肝细胞癌风险预测,性能优于PAGE-B、改良PAGE-B、CU-HCC和REACH-B。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antiviral therapy improves hepatic fibrosis and reduces hepatocellular carcinoma (HCC) incidence. This study aimed to evaluate whether on-therapy changes in scores for fibrosis index based on 4 factors and aspartate aminotransferase-to-platelet ratio index are associated with HCC development and establish an HCC risk score model incorporating noninvasive fibrosis marker (NFM) response. METHODS: This multicenter study recruited 5,147 patients with chronic hepatitis B (4,028 for derivation cohort and 1,119 for validation cohort) who were given entecavir/tenofovir for >12 months between 2007 and 2018. A risk prediction model for HCC was developed using predictors based on multivariable Cox models, and bootstrapping was performed for validation. RESULTS: The 10-year cumulative HCC incidence rates were 12.6% and 13.7% in the derivation and validation cohorts, respectively. The risk of HCC significantly differed with early NFM response, with a marked reduction in HCC risk in patients achieving a significant decrease in NFM by 12 months (P < 0.001). NFM response, sex, age, and cirrhosis were independently predictive of HCC. We developed the Fibrosis marker response, Sex, Age, and Cirrhosis (FSAC) score based on regression coefficients of each variable. For the 10-year prediction of HCC, FSAC showed higher C-index values than PAGE-B, modified PAGE-B, CU-HCC, and REACH-B (0.84 vs 0.77, 0.80, 0.77, and 0.67, respectively; all P < 0.005). The predictive performance of FSAC was corroborated in the validation cohort, with higher C-index than other models (all P < 0.050). DISCUSSION: On-therapy changes in NFM are an independent indicator of HCC risk. FSAC incorporating NFM response is a reliable risk score for risk estimation for HCC with better performance than other models.
引用
- Nam H, Lee SW, Kwon JH, et al. Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B. Am J Gastroenterol. 2021. PMID: 33734114. doi:10.14309/ajg.0000000000001219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。